A moss population has just released millions of spores after…

Questions

A mоss pоpulаtiоn hаs just releаsed millions of spores after a rainstorm. Arrange the next stages of its life cycle in order:

Gаstritis 1. Bаckgrоund Definitiоn: Inflаmmatiоn or injury of the gastric mucosa, which may be acute (short-term mucosal irritation) or chronic (persistent inflammation leading to mucosal atrophy or metaplasia). Pathophysiology: Acute gastritis: Direct mucosal injury from acid, NSAIDs, alcohol, bile reflux, or stress → mucosal edema, erosion, hemorrhage. Chronic gastritis: Persistent inflammation, often from H. pylori infection or autoimmune destruction of parietal cells (type A). Types: Type A (autoimmune) — body/fundus predominant; leads to B12 deficiency and pernicious anemia. Type B (H. pylori–related) — antral predominant; most common form worldwide. Epidemiology: Very common; risk increases with NSAID use, age, and H. pylori prevalence. 2. History Symptoms: Epigastric pain, nausea, vomiting, early satiety, bloating; may be asymptomatic. Alarm features: Hematemesis, melena, anemia, weight loss. Risk factors: NSAIDs, aspirin, alcohol, corticosteroids, stress (ICU/trauma), H. pylori infection, autoimmune disorders, smoking. Autoimmune gastritis clues: Fatigue, pallor, glossitis, or neuropathy (vitamin B12 deficiency). 3. Exam Findings Often normal or mild epigastric tenderness. Signs of anemia (pallor, tachycardia) if bleeding or B12 deficiency. In severe stress cases: hypotension or occult GI bleeding. 4. Making the Diagnosis Gold standard: Upper endoscopy (EGD) with biopsy — shows mucosal erythema, erosions, or atrophy and allows H. pylori testing. Commonly used alternatives: Urea breath test or stool antigen for H. pylori when endoscopy not indicated. CBC to evaluate for anemia; B12 level if autoimmune suspected. Indications for endoscopy: Alarm symptoms, persistent pain, or risk factors for malignancy. 5. Management A. Lifestyle / Supportive Stop offending agents (NSAIDs, alcohol). Small, frequent meals; avoid irritant foods and caffeine. B. Medication H. pylori–positive: Eradication therapy (PPI + clarithromycin + amoxicillin or bismuth quadruple regimen). NSAID-related: Discontinue NSAID; start PPI for 4–8 weeks. Stress gastritis (ICU): IV PPI or H2 blocker prophylaxis. Autoimmune: Treat B12 deficiency; monitor for gastric carcinoma or carcinoid risk. C. Complications Peptic ulcer formation, upper GI bleeding, iron or B12 deficiency, increased risk of gastric adenocarcinoma (chronic forms). Question A 58-year-old woman presents with fatigue and mild epigastric discomfort. She denies NSAID or alcohol use. Physical examination reveals a smooth, red tongue and decreased vibratory sensation in the lower extremities. Laboratory testing shows hemoglobin of 10.2 g/dL and mean corpuscular volume of 110 fL. Which of the following is the most likely underlying cause of this patient’s gastritis?

Cоlоrectаl Cаrcinоmа (CRC) 1. Background Definition: Malignant neoplasm of the colon or rectum, most commonly adenocarcinoma arising from the adenoma–carcinoma sequence. Pathophysiology: Stepwise accumulation of genetic mutations (APC → KRAS → p53) leads to dysplasia and carcinoma. Alternative pathway: microsatellite instability (e.g., Lynch syndrome). Epidemiology: 3rd most common cancer and 2nd leading cause of cancer death in the U.S. Incidence rises sharply after age 50 (screening now begins at 45). Risk factors: Modifiable: Low-fiber/high-fat diet, red/processed meat, obesity, smoking, alcohol, sedentary lifestyle. Nonmodifiable: Family history, adenomatous polyps, IBD (especially ulcerative colitis), hereditary syndromes (FAP, Lynch). 2. History Symptoms: Often asymptomatic early; discovered by screening. Right-sided (proximal): Occult bleeding → iron-deficiency anemia, fatigue. Left-sided (distal): Change in bowel habits, constipation alternating with diarrhea, rectal bleeding, narrowing of stool caliber. Rectal cancer: Tenesmus, hematochezia. Systemic findings: Weight loss, fatigue, or unexplained anemia. History clues: Family history of colon polyps, colon cancer, or Lynch-associated cancers (endometrial, ovarian, gastric). 3. Exam Findings General: Pallor (from anemia), weight loss. Abdominal: May show mass or distension in advanced disease. Rectal exam: Heme-positive stool, palpable mass if distal. Late findings: Hepatomegaly (metastasis), ascites, or lymphadenopathy. 4. Making the Diagnosis Gold standard: Colonoscopy with biopsy — diagnostic and allows for polyp removal. Screening recommendations (USPSTF 2021): Begin at age 45 for average risk; continue until 75. Earlier or more frequent screening for high-risk patients (family history, IBD, hereditary syndromes). Screening options: Colonoscopy every 10 years (preferred). FIT annually or FIT-DNA every 3 years. CT colonography every 5 years. Staging workup: CT chest/abdomen/pelvis for metastasis. CEA (carcinoembryonic antigen): Used for baseline and postoperative surveillance, not diagnosis. 5. Management A. Surgical Treatment Localized disease: Segmental colectomy with lymph node dissection (curative intent). Rectal cancer: Low anterior resection or abdominoperineal resection depending on location. B. Adjuvant / Neoadjuvant Therapy Stage III (node-positive) or high-risk Stage II: Adjuvant chemotherapy (e.g., FOLFOX). Rectal cancer: Neoadjuvant chemoradiation to reduce recurrence risk. C. Advanced / Metastatic Disease Systemic chemotherapy ± targeted biologics (bevacizumab, cetuximab). Palliative care for unresectable disease. D. Surveillance Colonoscopy: 1 year post-resection, then every 3–5 years. CEA levels: Every 3–6 months for 5 years. CT imaging: Annually for 3–5 years for high-risk cases. E. Prevention High-fiber diet, exercise, limited red/processed meat, and aspirin chemoprevention (in select high-risk adults per USPSTF). Question A 47-year-old man with no significant past medical history presents for a routine health maintenance visit. He has no family history of colorectal cancer or polyps. He feels well and has no gastrointestinal symptoms. According to current U.S. Preventive Services Task Force (USPSTF) guidelines, which of the following is the most appropriate colorectal cancer screening recommendation for this patient?